Skip to main content
SpringerLink
Log in

Secukinumab cost effective for active disease in UK

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2017 British pounds

  2. nonsteroidal anti-inflammatory drugs and non-pharmacological interventions such as physiotherapy

References

  1. Buchanan V, et al. Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK. PharmacoEconomics : 25 May 2018. Available from: URL: https://doi.org/10.1007/s40273-018-0674-x.

  2. Emery P, et al. Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK. PharmacoEconomics : 25 May 2018. Available from: URL: https://doi.org/10.1007/s40273-018-0675-9.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Secukinumab cost effective for active disease in UK. PharmacoEcon Outcomes News 804, 31 (2018). https://doi.org/10.1007/s40274-018-4995-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4995-y

Search

Navigation